|
Prescription Drug Search
Strengths available for Bexarotene :
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about MyGlobalPharmacy.com
List of countries where we can ship Bexarotene:
- Albania
- Algeria
- Barbados
- Bermuda
- Bolivia
- Bulgaria
- China
- Colombia
- Czech Republic
- Egypt
- European Union
- Fiji
- Greece
- Greenland
- Honduras
- Hong Kong
- India
- Iraq
- Ireland
- Japan
- Morocco
- Netherlands
- Norway
- Panama
- Paraguay
- Qatar
- Saint Lucia
- Seychelles
- Spain
- Sri Lanka
- Sweden
- Thailand
- Trinidad and Tobago
- Tunisia
- United Arab Emirates
- United Kingdom, UK
- United States, US
- Uruguay
- Uzbekistan
- Vanuatu
Latest news releases on Bexarotene:
Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL - News-Medical.Net
The trial will assess ADCETRIS versus investigator's choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with pcALCL or MF. The primary endpoint of the study is overall response rate lasting at least 4 months.
Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma - Genetic Engineering News
The study is a randomized, open-label, phase 3 trial of ADCETRIS versus investigator’s choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with primary cutaneous anaplastic large cell lymphoma (pcALCL ...
Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell Lymphoma - Yahoo Finance
The trial will assess ADCETRIS versus investigator’s choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with pcALCL or MF. The primary endpoint of the study is overall response rate lasting at least 4 months.
Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS(TM) in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma - Marketwatch
Study design The study is a randomized, open-label, phase 3 trial of ADCETRIS versus investigator's choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with primary cutaneous anaplastic large cell lymphoma ...
Seattle Genetics presents phase II trial results of ADCETRIS in CTCL at Society for Investigative Dermatology meeting - pharmabiz.com
The trial will assess ADCETRIS versus investigator’s choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with pcALCL or MF. The primary endpoint of the study is overall response rate lasting at least 4 months.
